Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales
Portfolio Pulse from
Geron Corporation's RYTELO, approved by the FDA for Low-Risk Myelodysplastic Syndrome, is awaiting European approval. The company reported $28.2 million in sales for the first full quarter, with projections of $45-$46 million for Q4 2024. A Phase 3 study for RYTELO targeting Myelofibrosis patients is underway, with interim results expected by early 2026.
January 16, 2025 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Geron Corporation's RYTELO, approved by the FDA, is awaiting European approval, which could boost sales. The company projects significant sales growth and is conducting a Phase 3 study for further indications.
The FDA approval and potential European approval of RYTELO are significant regulatory milestones that could lead to increased sales. The ongoing Phase 3 study for additional indications further supports potential growth, making the news highly relevant and important for Geron's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100